There are currently 1290 clinical trials in Miami, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Miami, GSK Investigational Site, University of Miami Miller School of Medicine-Sylvester Cancer Center and University of Miami Miller School of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Multimodal Pain Package vs. Regular Formulation for Pain Management in Ambulatory Spinal Surgery
NCT05965492
Recruiting
The purpose of this research is to compare two outpatient pain management strategies in patients undergoing spinal surgeries such as microdiscectomies, foraminotomies, and spinal decompressions.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: University of Miami, Miami, Florida +1 locations
Conditions: Spinal Disorder
Register for Updates
A Study of the THERMOCOOL SMARTTOUCH Surround Flow (SF) Catheter With the TRUPULSE Generator for Treatment of Drug Refractory Symptomatic PAF
NCT06144632
Recruiting
The purpose of this study is to demonstrate safety and effectiveness of the Biosense Webster (BWI) ablation system (THERMOCOOL SMARTTOUCH surround flow [STSF] catheter and TRUPULSE generator) when used for isolation of the atrial pulmonary veins (PVs) in treatment of participants with paroxysmal atrial fibrillation (PAF), an irregular heart rate that causing abnormal blood flow.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/18/2024
Locations: HCA Florida Mercy Hospital, Miami, Florida
Conditions: Drug Refractory Paroxysmal Atrial Fibrillation
Register for Updates
A Study of Aticaprant as Adjunctive Therapy in Adult Participants With Major Depressive Disorder (MDD) With Moderate-to-severe Anhedonia and Inadequate Response to Current Antidepressant Therapy
NCT05455684
Recruiting
The purpose of this study is to evaluate the efficacy of aticaprant compared with placebo as adjunctive therapy to an antidepressant in improving depressive symptoms in adult participants with major depressive disorder (MDD) with moderate-to-severe anhedonia (ANH+) who have had an inadequate response to current antidepressant therapy with a selective serotonin reuptake inhibitor (SSRI) or serotonin-norepinephrine reuptake inhibitor (SNRI).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2024
Locations: Pharmax Research Clinic Inc, Miami, Florida +1 locations
Conditions: Depressive Disorder, Major, Anhedonia
Register for Updates
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
NCT06144840
Recruiting
To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in adults and adolescents with EPP or XLP.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
06/18/2024
Locations: University Of Miami School Of Medicine, Center For Liver Diseases, Miami, Florida
Conditions: Erythropoietic Protoporphyria (EPP), X-Linked Protoporphyria (XLP)
Register for Updates
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
NCT02402660
Recruiting
The purpose of this study is to determine the long term safety and tolerability of ALK-001 (C20-D3-retinyl acetate), and to explore the effects of ALK-001 on the progression of Stargardt disease in patients between the ages of 8 and 70 years old. Funding Source - FDA OOPD
Gender:
All
Ages:
Between 8 years and 70 years
Trial Updated:
06/18/2024
Locations: University of Miami - Bascom Palmer Eye Institute, Miami, Florida
Conditions: Stargardt Disease, Stargardt Macular Degeneration, Stargardt Macular Dystrophy, Autosomal Recessive Stargardt Disease 1 (ABCA4-related)
Register for Updates
A Multiple-Dose Study of Bulevirtide in Participants With Normal and Impaired Renal Function
NCT05760300
Recruiting
The goals of this study are to compare the amount of study drug, bulevirtide (BLV), that gets into the bloodstream and how long it takes for the body to eliminate it, measure the effect of BLV on bile acids, and evaluate the safety and tolerability of multiple doses of BLV in participants with normal or impaired renal (kidney) function.
Gender:
All
Ages:
Between 18 years and 79 years
Trial Updated:
06/18/2024
Locations: Clinical Pharmacology of Miami, LLC, Miami, Florida +1 locations
Conditions: Chronic Hepatitis D Infection
Register for Updates
Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy
NCT06333808
Recruiting
The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose combination (FDC) versus current therapy bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) FDC in people living with HIV-1 (PWH). The primary objective of this study is to learn how effective it is to switch to BIC/LEN FDC tablets versus continuing on B/F/TAF FDC tablets in virologically suppressed PWH.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/18/2024
Locations: AIDS Healthcare Foundation - The Kinder Medical Group, Miami, Florida
Conditions: HIV-1-infection
Register for Updates
A Study of Vaccination With 9-valent Extraintestinal Pathogenic Escherichia Coli Vaccine (ExPEC9V) in the Prevention of Invasive Extraintestinal Pathogenic Escherichia Coli Disease in Adults Aged 60 Years And Older With a History of Urinary Tract Infection in the Past 2 Years
NCT04899336
Recruiting
The purpose of this study is to demonstrate the efficacy of 9-valent extraintestinal pathogenic Escherichia coli vaccine (ExPEC9V) compared to placebo in the prevention of the first invasive extraintestinal pathogenic Escherichia coli disease (IED) event caused by ExPEC9V O-serotypes.
Gender:
All
Ages:
60 years and above
Trial Updated:
06/18/2024
Locations: Nova Clinical Research Center, Miami, Florida +12 locations
Conditions: Invasive Extraintestinal Pathogenic Escherichia Coli Disease (IED) Prevention
Register for Updates
A Study of Daratumumab
NCT05438043
Recruiting
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have... Read More
Gender:
All
Ages:
All
Trial Updated:
06/18/2024
Locations: University of Miami Sylvester Cancer Center, Miami, Florida
Conditions: Multiple Myeloma
Register for Updates
A Study of Aticaprant in Adult and Elderly Participants With Major Depressive Disorder (MDD)
NCT05518149
Recruiting
The purpose of this study is to assess the long-term safety and tolerability of aticaprant administered as adjunctive therapy to a current antidepressant (selective serotonin reuptake inhibitor [SSRI] or serotonin and norepinephrine reuptake inhibitor [SNRI]) in all participants with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 74 years
Trial Updated:
06/18/2024
Locations: Vital Care Research, Miami, Florida +7 locations
Conditions: Depressive Disorder, Major
Register for Updates
Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults
NCT05615220
Recruiting
This Phase 3 multicenter study evaluates the maintenance of efficacy, safety and tolerability of ecopipam tablets in children, adolescents and adults in the treatment of Tourette's Disorder (TD). The study includes an open-label period followed by double-blind, placebo-controlled, randomized withdrawal period.
Gender:
All
Ages:
6 years and above
Trial Updated:
06/18/2024
Locations: University of Miami Miller School of Medicine, Miami, Florida +3 locations
Conditions: Tourette Disorder
Register for Updates
Study to Explore the Therapeutic Effect of Eluxadoline in Treating Irritable Bowel Syndrome With Diarrhea in Children
NCT03339128
Recruiting
The primary objectives of this study are to explore the therapeutic effect of eluxadoline in treating irritable bowel syndrome with diarrhea (IBS-D) in pediatric participants 6-17 years of age, to evaluate the pharmacokinetics of eluxadoline in pediatric participants with IBS-D, and to evaluate the safety and tolerability of eluxadoline in pediatric participants with IBS-D. Enrollment of 12-17 years old age group is closed, enrollment of the 6-11 years old age group will continue.
Gender:
All
Ages:
Between 6 years and 17 years
Trial Updated:
06/18/2024
Locations: Sunrise Research Institute /ID# 237382, Miami, Florida +3 locations
Conditions: Irritable Bowel Syndrome
Register for Updates